Mutant huntingtin expression in the hypothalamus promotes ventral striatal neuropathology
Rana Soylu-KucharziD, Natalie Adlesic, Marcus DavidssoniD, Tomas BjörklundiD, Maria BjörkqvistiD, Åsa PeterséniD
Abstract
Huntingtons disease is a fatal neurodegenerative disorder caused by an expanded CAG triplet repeat in the huntingtin (HTT) gene. Previous research focused on neuropathology in the striatum and its association with a typical movement disorder. Direct effects of mutant HTT (mHTT) in the striatum may cause neuropathology, although non-cell autonomous effects have also been suggested. Important non-motor features of HD include psychiatric symptoms and metabolic dysfunction, which may be linked to hypothalamic neuropathology. As hypothalamic neurons project to the ventral striatum, we hypothesized that expression of mHTT in the hypothalamus leads to disrupted neurotransmission in the ventral striatum and causes pathology. The overall aim of this study was to investigate the impact of mHTT expression in the hypothalamus on ventral striatal neuropathology and its contribution to non-HD motor symptoms. We demonstrate that selective expression of mHTT in the hypothalamus leads to the loss of dopamine and cAMP-regulated phosphoprotein (DARPP-32) immunopositive neurons in the ventral striatum in mice. Contrary to the effects of direct expression of mHTT in the hypothalamus, selective overexpression of mHTT in the ventral striatum does not affect body weight. Selective expression of mHTT in the ventral striatum leads to mHTT inclusion formation and loss of DARPP-32 neurons without affecting motor activity or anxiety-like behavior. We show that DARPP-32 neuron loss in the ventral striatum is recapitulated in the R6/2 mouse model of HD. Chemogenetic activation of hypothalamic neurons projecting to the ventral striatum had a blunted response in the R6/2 mice compared to wild-type mice, indicating a disrupted hypothalamus-ventral striatal circuitry. In summary, the expression of mHTT in the hypothalamus may impact the development of ventral striatal pathology in mice. This opens the possibility that non-cell-autonomous effects in the reward circuitry play a role in HD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease
Jo B. Henningsen, Rana Soylu-Kucharz, … Åsa Petersén·HeliyonPeer-reviewed·Aug 1, 2021
- Enhanced Hippocampal Spare Capacity in Q175DN Mice Despite Elevated mHTT Aggregation
Melissa A Solem, Ross J. Pelzel, … Rocío Gómez‐Pastor·bioRxiv·Oct 14, 2024
- Microarray profiling of hypothalamic gene expression changes in Huntington's disease mouse models
Elna Dickson, Amoolya Sai Dwijesha, … Rana Soylu-Kucharz·Frontiers in NeurosciencePeer-reviewed·Nov 3, 2022
- Striatal neuron excitability is regulated by huntingtin in the adult brain
Jessica C. Barron, Meghan L. Greenland, … Matthew P. Parsons·eNeuroPeer-reviewed·May 28, 2026
- Developmental alterations of indirect-pathway medium spiny neurons in mouse models of Huntington's disease.
Margaux Lebouc, Léa Bonamy, … Maurice Garret·Neurobiology of DiseasePeer-reviewed·Mar 14, 2025
- M2 Cortex-Dorsolateral striatum stimulation reverses motor symptoms and synaptic deficits in Huntington's Disease
Sara Fernández‐García, Sara Conde-Berriozabal, … Mercè Masana·eLifePeer-reviewed·Oct 5, 2020